Aytu BioPharma, Inc. (Nasdaq: AYTU) reported its fiscal 2027 first quarter operational and financial results for the period ended September 30, 2026. The company announced that due to a pending merger, it will not hold an earnings conference call to discuss the results.

For the first quarter of fiscal 2027, Aytu reported net revenue of $14.8 million, a 6.9% increase compared to $13.9 million in the prior-year period. The company’s revenue was driven by its ADHD and Pediatric portfolios, though the ADHD portfolio saw a decrease compared to the prior year due to reduced promotional emphasis and generic competition.

Key financial metrics for the quarter included:

On November 16, 2026, Aytu announced it entered into a definitive merger agreement with Rosemont Pharmaceuticals Holdings, Inc. Under the terms of the agreement, Rosemont will acquire Aytu through a cash tender offer for $2.70 per share, followed by a merger. The total consideration is approximately $56 million on a fully-diluted basis. The transaction is expected to be completed by the end of calendar 2026, subject to the tender of a majority of the outstanding shares of Aytu common stock and the satisfaction of customary closing conditions.